Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis
Standard
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis. / Reich, Kristian; Lio, Peter A; Bissonnette, Robert; Alexis, Andrew F; Lebwohl, Mark G; Pink, Andrew E; Kabashima, Kenji; Boguniewicz, Mark; Nowicki, Roman J; Valdez, Hernan; Zhang, Fan; DiBonaventura, Marco; Cameron, Michael C; Clibborn, Claire.
In: J ALLER CL IMM-PRACT, Vol. 10, No. 12, 12.2022, p. 3228-3237.e2.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis
AU - Reich, Kristian
AU - Lio, Peter A
AU - Bissonnette, Robert
AU - Alexis, Andrew F
AU - Lebwohl, Mark G
AU - Pink, Andrew E
AU - Kabashima, Kenji
AU - Boguniewicz, Mark
AU - Nowicki, Roman J
AU - Valdez, Hernan
AU - Zhang, Fan
AU - DiBonaventura, Marco
AU - Cameron, Michael C
AU - Clibborn, Claire
N1 - Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2022/12
Y1 - 2022/12
N2 - BACKGROUND: Emerging treatments for moderate-to-severe atopic dermatitis (AD) may provide greater and faster improvement in AD signs and symptoms than current therapies.OBJECTIVE: To examine JADE COMPARE (NCT03720470) data using stringent efficacy end points.METHODS: Adults with moderate-to-severe AD were randomly assigned 2:2:2:1 to receive oral abrocitinib 200 or 100 mg once daily, subcutaneous dupilumab 300 mg every 2 weeks (600-mg loading dose), or placebo, with medicated topical therapy for 16 weeks. Stringent response thresholds were applied for Eczema Area and Severity Index (EASI), Investigator's Global Assessment, Dermatology Life Quality Index, Peak Pruritus Numerical Rating Scale, and Night Time Itch Scale severity.RESULTS: At week 16, 48.9%, 38.0%, and 38.8% of the abrocitinib 200-mg, 100-mg, and dupilumab groups, respectively, achieved greater than or equal to 90% improvement from baseline in EASI versus 11.3% placebo; 14.9%, 12.6%, and 6.5% achieved Investigator's Global Assessment 0 (clear) versus 4.8% placebo; 29.7%, 21.6%, and 24.0% achieved Dermatology Life Quality Index 0/1 (no/minimal impact on quality of life) versus 10.6% placebo; and 57.1%, 44.5%, and 46.1% achieved Night Time Itch Scale severity 0/1 (no/minimal night-time itch) versus 31.9% placebo. Kaplan-Meier median time to greater than or equal to 90% improvement from baseline in EASI was 59, 113, and 114 days in the abrocitinib 200-mg, 100-mg, and dupilumab groups, respectively, and was not evaluable for placebo; median time to Peak Pruritus Numerical Rating Scale 0/1 (no/very minimal itch) was 86 and 116 days for abrocitinib 200-mg and dupilumab groups, respectively, and was not evaluable for abrocitinib 100-mg and placebo groups.CONCLUSIONS: A greater proportion of patients treated with abrocitinib than placebo had almost complete control of AD signs and symptoms.
AB - BACKGROUND: Emerging treatments for moderate-to-severe atopic dermatitis (AD) may provide greater and faster improvement in AD signs and symptoms than current therapies.OBJECTIVE: To examine JADE COMPARE (NCT03720470) data using stringent efficacy end points.METHODS: Adults with moderate-to-severe AD were randomly assigned 2:2:2:1 to receive oral abrocitinib 200 or 100 mg once daily, subcutaneous dupilumab 300 mg every 2 weeks (600-mg loading dose), or placebo, with medicated topical therapy for 16 weeks. Stringent response thresholds were applied for Eczema Area and Severity Index (EASI), Investigator's Global Assessment, Dermatology Life Quality Index, Peak Pruritus Numerical Rating Scale, and Night Time Itch Scale severity.RESULTS: At week 16, 48.9%, 38.0%, and 38.8% of the abrocitinib 200-mg, 100-mg, and dupilumab groups, respectively, achieved greater than or equal to 90% improvement from baseline in EASI versus 11.3% placebo; 14.9%, 12.6%, and 6.5% achieved Investigator's Global Assessment 0 (clear) versus 4.8% placebo; 29.7%, 21.6%, and 24.0% achieved Dermatology Life Quality Index 0/1 (no/minimal impact on quality of life) versus 10.6% placebo; and 57.1%, 44.5%, and 46.1% achieved Night Time Itch Scale severity 0/1 (no/minimal night-time itch) versus 31.9% placebo. Kaplan-Meier median time to greater than or equal to 90% improvement from baseline in EASI was 59, 113, and 114 days in the abrocitinib 200-mg, 100-mg, and dupilumab groups, respectively, and was not evaluable for placebo; median time to Peak Pruritus Numerical Rating Scale 0/1 (no/very minimal itch) was 86 and 116 days for abrocitinib 200-mg and dupilumab groups, respectively, and was not evaluable for abrocitinib 100-mg and placebo groups.CONCLUSIONS: A greater proportion of patients treated with abrocitinib than placebo had almost complete control of AD signs and symptoms.
KW - Adult
KW - Humans
KW - Dermatitis, Atopic/drug therapy
KW - Quality of Life
KW - Severity of Illness Index
KW - Double-Blind Method
KW - Treatment Outcome
KW - Pruritus/drug therapy
U2 - 10.1016/j.jaip.2022.08.042
DO - 10.1016/j.jaip.2022.08.042
M3 - SCORING: Journal article
C2 - 36108923
VL - 10
SP - 3228-3237.e2
JO - J ALLER CL IMM-PRACT
JF - J ALLER CL IMM-PRACT
SN - 2213-2198
IS - 12
ER -
